By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish on Oscar Health (OSCR), citing extreme volatility in medical loss ratios, aggressive pricing assumptions, and thin margins that could evaporate with utilization trends or regulatory headwinds. The single biggest risk flagged is the potential collapse of the entire ACA marketplace due to subsidy expiration, which would disproportionately impact OSCR given its reliance on ACA exchanges for revenue.
Risk: Subsidy expiration and resulting adverse selection spikes
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Healthcare may not be as hot an industry as space or artificial intelligence (AI), but it's much larger than either today. Trillions of dollars are spent on healthcare in the United States every year, a figure that's set to grow faster than inflation as the country's average age rises over the next few decades.
It is a massive industry ripe for disruption, with stakeholders across the board upset with legacy systems, such as traditional health insurance, that underperform for customers. Some brave companies are trying to change this paradigm, such as Oscar Health (NYSE: OSCR).
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
The start-up health insurer is up 90% this year, and with a market cap of just $8.6 billion, it still has plenty of room to grow in the years ahead. Here's why the stock is still a buy for investors in 2026 and beyond.
Oscar Health was founded back in 2012 to take advantage of the new Affordable Care Act (ACA) health insurance marketplace. After the new health insurance laws were enacted during the Obama administration, more individuals were paying for coverage through state-regulated marketplaces, which Oscar wanted to address.
Through fits and starts, Oscar has grown its customer base over the past few years at roughly the pace of the ACA marketplace, while also taking market share from existing players. At the end of last quarter, it had 3.2 million customers, making it one of the largest players in the ACA marketplace.
How has Oscar Health done this? It's pretty simple: The company provides a better customer experience at a price similar to other health insurance plans. Through services like free telehealth, dedicated online customer-service reps, and modern digital tools, Oscar Health has achieved much higher customer satisfaction than old-school health insurance companies, which are not well-liked by many customers.
Oscar Health has not been consistently profitable over its history, but that's due to the necessary scale needed to operate a health insurer in all 50 states. Now, with millions of Oscar health insurance customers, the company is finally leveraging its network to generate more revenue without the proportional increase in baseline expenses.
This year, Oscar Health has set the high end of its guidance at $19 billion in revenue and $450 million in operating earnings, both records for the company. Last quarter, it reported $700 million in operating income, which was actually higher than its total guidance for 2026. This happens because of increased healthcare utilization throughout the year, as well as some initial payors for health insurance deciding to ditch monthly payments as the year progresses.
Over the next three quarters, Oscar Health is guiding to lose money. But this would still put it on target to hit or exceed its 2026 earnings guidance, which is why the stock has begun to rocket higher this year.
With a vast population in the United States and only 3.2 million customers at the end of last quarter, there is plenty of room for Oscar Health to grow its insurance premiums in the years ahead. As long as it operates efficiently, this will lead to billions of dollars in profits.
One of the great investing adages is to let your winners ride; for anyone holding Oscar Health stock, remember this. And if you still haven't bought, don't let the 90% share-price pop this year dissuade you.
Oscar Health's $19 billion in 2026 premium revenue could more than double to $50 billion if it doubles its total customers to 6.5 million over the next five years. Just a few years ago, the number of total customers was under 1 million, so this is not an unreasonable assumption.
Health insurers operate on thin margins, but even a 5% operating margin on $50 billion in premium revenue would mean $2.5 billion in annual operating income. Today, Oscar Health stock has a market cap of $8.6 billion, or just 3.5 times what the business may earn a few years from now.
This potential makes Oscar Health stock a great buy today, even though it's up 90% this year. Just make sure to hold on for a long time.
Before you buy stock in Oscar Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Oscar Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $433,268! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,259,391!
Now, it’s worth noting Stock Advisor’s total average return is 935% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 14, 2026. *
Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The valuation assumes linear growth in a highly cyclical, regulatory-sensitive insurance segment that historically struggles to maintain underwriting profitability at scale."
Oscar Health (OSCR) is trading at a premium based on the assumption that it can scale ACA marketplace membership while maintaining underwriting discipline. While the 90% rally reflects a shift toward positive operating income, the article glosses over the extreme volatility of medical loss ratios (MLR) in the individual market. Scaling from 3.2 million to 6.5 million members requires aggressive pricing that often invites adverse selection—where sicker individuals disproportionately join the plan. With a market cap of $8.6 billion, the stock is pricing in perfection. If utilization trends spike or regulatory headwinds emerge in the ACA exchanges, the 'record' operating income could evaporate, leaving investors holding a high-beta insurer with thin margins.
If Oscar’s proprietary 'Oscar Platform' effectively lowers administrative costs and improves clinical outcomes, they could achieve a structural cost advantage that allows them to underprice legacy incumbents while maintaining superior margins.
"OSCR's 2026 guidance includes a $700M Q1 operating income followed by three quarters of losses, yet the article treats this as evidence of sustainable profitability rather than seasonal/one-time benefit masking structural margin pressure."
Oscar Health's 90% YTD run is real, but the article's math is dangerously loose. It assumes OSCR doubles customers to 6.5M by 2030 and maintains 5% operating margins—both aggressive. The Q1 $700M operating income is misleading: the article admits Q2-Q4 guidance is negative, suggesting front-loaded seasonality or one-time benefits, not sustainable profitability. At 3.5x forward earnings on a $50B revenue fantasy, OSCR is priced for perfection. Medical loss ratios (MLRs) in ACA are structurally volatile; one bad flu season or adverse selection cohort could crater margins. The article ignores competitive response from UnitedHealth, Anthem, and Cigna—they have distribution, scale, and pricing power OSCR lacks.
If OSCR's tech-driven customer experience genuinely reduces medical utilization and improves retention vs. legacy insurers, the margin expansion thesis isn't fantasy—it's the only way a startup insurer survives long-term. The stock could compound 15%+ annually for a decade if execution holds.
"Oscar Health faces material risk that medical cost pressures and regulatory exposure will prevent it from achieving the sustained high margins needed to justify even current valuation."
The article highlights OSCR's ACA marketplace share gains to 3.2 million members and 2026 guidance of $19B revenue with $450M operating earnings, implying a cheap 3.5x multiple on potential future profits. However, it underplays how thin-margin health insurance profits hinge on medical loss ratios staying controlled amid utilization spikes and cost inflation. OSCR's history of losses and quarterly guidance for red ink next three quarters signal execution risk as it scales. Political shifts in ACA subsidies or enhanced competition from scale players like UNH and CNC could cap premium growth far below the assumed doubling to $50B.
OSCR's digital tools and telehealth edge could drive faster member retention and share gains than peers, allowing margins to expand steadily if utilization normalizes.
"The core risk is that Oscar Health's profitability hinges on aggressive enrollment growth and favorable cost dynamics that may not materialize, leaving upside highly sensitive to policy and utilization shocks."
Oscar Health's story rests on scale: from 3.2M to about 6.5M customers would double enrollments, underpinning a claimed 5% operating margin on up to $50B of premium revenue. That calculus assumes favorable risk pools, steady subsidy support, and cost discipline—rare mix for a health insurer. Near-term quarters show losses as we absorb onboarding and marketing costs, and insurance economics can deteriorate quickly if medical costs rise or payouts shift. The article glosses over regulatory risk, competition from established insurers, and the sensitivity of margins to utilization and payer contracting. Valuation may be optimistic if growth slows or policy support wanes.
Against: the '5% margin on $50B' assumption ignores medical inflation, risk-adjustment variability, and payer dynamics; near-term losses imply a fragile cash trajectory, not a smooth path to profitability. Any ACA subsidy tension or regulatory change could erode the moat and cap upside.
"The entire OSCR growth thesis is contingent on federal subsidy extensions that face significant legislative risk."
Claude, your focus on the '5% margin on $50B' is the right trap to highlight, but you're missing the regulatory 'cliff' risk. ACA subsidies are currently propping up the entire market; if Congress fails to extend these enhanced tax credits, the total addressable market for OSCR collapses overnight, regardless of their tech stack. The stock isn't just priced for perfection; it's priced for a permanent legislative status quo that is historically fragile.
"ACA subsidy risk is systemic, not OSCR-specific; the real bear case is OSCR's margin fragility relative to diversified incumbents if utilization normalizes."
Gemini's legislative cliff is real, but we're conflating two separate risks. ACA subsidy expiration would crater the *entire* marketplace—UNH, Anthem, Cigna all suffer equally. That's macro, not OSCR-specific. The actual OSCR risk is *relative* underperformance: if subsidies hold but utilization spikes, OSCR's thin margins compress faster than incumbents with diversified revenue (Medicare Advantage, employer). The stock prices in legislative stability *and* operational perfection. Either breaks it.
"OSCR's near-total ACA concentration converts broad subsidy risk into company-specific survival pressure."
Claude notes subsidy expiration hits everyone equally, but OSCR derives nearly all revenue from ACA exchanges unlike diversified peers. A lapse would trigger adverse selection spikes and enrollment drops for OSCR specifically, as low-income members exit first. This concentration turns the macro event into an existential threat, pressuring its thin margins faster than incumbents with MA and employer segments can offset.
"OSCR’s value hinges on turning enrollment growth into durable margins, and subsidy risk is real, but the bigger near-term danger is margin quality under adverse selection and rising medical costs."
Grok, the 'existential' framing overstates the issue. Subsidy risk matters, but OSCR’s core risk is margin quality as it scales: adverse selection, medical cost inflation, and payer contracting dynamics. If enrollment climbs but costs outpace pricing, the 5% margin thesis collapses. A subsidy cliff would hurt everyone, but OSCR’s moat hinges on converting growth into durable profitability, which remains unproven versus incumbents.
The panel consensus is bearish on Oscar Health (OSCR), citing extreme volatility in medical loss ratios, aggressive pricing assumptions, and thin margins that could evaporate with utilization trends or regulatory headwinds. The single biggest risk flagged is the potential collapse of the entire ACA marketplace due to subsidy expiration, which would disproportionately impact OSCR given its reliance on ACA exchanges for revenue.
Subsidy expiration and resulting adverse selection spikes